L’efficacité à long-terme du nintédanib est maintenue chez les patients atteints de fibrose pulmonaire idiopathique (FPI) quelle que soit la dose : analyse de sous-groupe de l’étude INPULSIS-ON
Sign Up to like & getrecommendations! Published in 2018 at "Revue Des Maladies Respiratoires"
DOI: 10.1016/j.rmr.2017.10.309
Abstract: Introduction Lors des essais INPULSIS de phase III, le nintedanib a reduit significativement le taux annuel de declin de la capacite vitale forcee (CVF) par rapport au placebo chez les patients atteints de FPI (−113,6 versus… read more here.
Keywords: chez les; les patients; bid; inpulsis ... See more keywords
Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials
Sign Up to like & getrecommendations! Published in 2017 at "Respirology"
DOI: 10.1111/resp.12960
Abstract: Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia. Nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) compared with placebo in patients with IPF in… read more here.
Keywords: idiopathic pulmonary; japanese patients; pulmonary fibrosis; inpulsis ... See more keywords
Patterns of discontinuation in patients with IPF treated with open-label nintedanib: data from INPULSIS-ON
Sign Up to like & getrecommendations! Published in 2018 at "European Respiratory Journal"
DOI: 10.1183/13993003.congress-2018.pa4777
Abstract: INPULSIS®-ON Ulrich Costabel,1 Michael Kreuter,2 Jin Woo Song,3 John T Huggins,4 Benoit Wallaert,5 Wibke Stansen,6 Susanne Stowasser,6 Manuel Quaresma,6 Bruno Crestani7 1Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, Germany; 2Center for Interstitial and Rare Lung… read more here.
Keywords: ipf treated; patterns discontinuation; patients ipf; university ... See more keywords
Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
Sign Up to like & getrecommendations! Published in 2020 at "Respiratory Research"
DOI: 10.1186/s12931-020-1298-1
Abstract: Background In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibrosis (IPF) with nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing disease… read more here.
Keywords: health related; hrqol; inpulsis; related quality ... See more keywords